文献速递肝病

未治疗的HBeAg阴性且HBsAg<100 IU/mL的慢性乙型肝炎病毒感染患者预后良好

Favourable Prognosis of Patients With Untreated HBeAg-Negative Chronic Hepatitis B Virus Infection With HBsAg < 100 IU/mL.
PubMed 文献 · Aliment Pharmacol Ther · 2024-11-11

该研究纳入来自三家医院的521例未治疗的HBeAg阴性、HBsAg<100 IU/mL且ALT正常的慢性HBV感染者,中位随访25.0个月。结果显示10.0%的患者实现自发性HBsAg清除,年清除率为4.2%;基线HBsAg≤10 IU/mL和男性与更高的HBsAg清除率相关,而HBsAg>10 IU/mL和可检测HBV DNA与向HBeAg阴性不确定期转变的风险相关。无患者发生HCC或致命结局。

要点

  • HBeAg阴性、HBsAg<100 IU/mL且ALT正常者预后良好,中位随访25.0个月无HCC或致命结局。
  • 自发性HBsAg清除率为10.0%,年清除率4.2%;基线HBsAg≤10 IU/mL(aHR=3.490)和男性(aHR=1.980)更易实现清除。
  • 基线HBsAg>10 IU/mL(aHR=3.846)和可检测HBV DNA(aHR=2.672)与向HBeAg阴性不确定期转变相关。

核心结论

  • HBeAg阴性、血清HBsAg<100 IU/mL且ALT正常的未治疗患者预后良好。
  • HBsAg≤10 IU/mL和男性与更高的HBsAg清除率相关,HBsAg>10 IU/mL和可检测HBV DNA与更高的向不确定期转变风险相关。

研究设计与样本

  • 来自三家医院的521例未治疗的HBeAg阴性、HBsAg<100 IU/mL且ALT正常的患者。
  • 分析自发性HBsAg清除、分期转变、肝纤维化进展和肝细胞癌(HCC)发生。

主要发现

  • 中位年龄43.0岁,62.2%为男性。
  • 中位随访25.0个月后,52例(10.0%)实现自发性HBsAg清除,年清除率4.2%。
  • 基线HBsAg≤10 IU/mL(aHR=3.490,p<0.001)和男性(aHR=1.980,p=0.041)更可能实现HBsAg清除。
  • 仅4例(0.8%)转变为免疫逃逸期,23例(4.8%)转变为HBeAg阴性不确定期。
  • 基线HBsAg>10 IU/mL(aHR=3.846,p=0.034)和可检测HBV DNA(aHR=2.672,p=0.023)与向HBeAg阴性不确定期转变相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Serum hepatitis B surface antigen (HBsAg) < 100 IU/mL has been recently proposed as one of the key criteria of 'partial cure' in patients with chronic hepatitis B virus (HBV) infection. We analysed the clinical prognosis of hepatitis B e antigen (HBeAg)-negative untreated patients with HBsAg < 100 IU/mL and normal alanine aminotransferase (ALT) levels. METHODS: Five hundred and twenty-one untreated patients with HBeAg negativity, HBsAg < 100 IU/mL and normal ALT levels were included from three hospitals. Spontaneous HBsAg seroclearance, phase transition, liver fibrosis progression and hepatocellular carcinoma (HCC) development were analysed. RESULTS: The median age was 43.0 years, and 62.2% of the patients were male. After a median follow-up of 25.0 months, 52 (10.0%) patients achieved spontaneous HBsAg seroclearance. The annual HBsAg seroclearance rate is 4.2%. Patients with baseline HBsAg ≤ 10 IU/mL (adjusted hazard ratio [aHR] = 3.490, p < 0.001) and male sex (aHR = 1.980, p = 0.041) were more likely to achieve HBsAg seroclearance. Only 4 (0.8%) and 23 (4.8%) patients transitioned to the immune escape phase and HBeAg-negative indeterminate phase, respectively. Baseline serum HBsAg > 10 IU/mL (aHR = 3.846, p = 0.034) and detectable HBV DNA (aHR = 2.672, p = 0.023) were associated with transition to the HBeAg-negative indeterminate phase. No patient developed HCC or had fatal outcomes. CONCLUSIONS: HBeAg-negative patients with serum HBsAg < 100 IU/mL and normal ALT levels had a favourable prognosis. HBsAg ≤ 10 IU/mL and male sex were associated with a higher rate of HBsAg seroclearance, while HBsAg > 10 IU/mL and detectable HBV DNA were associated with a higher risk of transition to the indeterminate phase.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Wang J, Zhang Z, Yin S, et al. Favourable Prognosis of Patients With Untreated HBeAg-Negative Chronic Hepatitis B Virus Infection With HBsAg < 100 IU/mL. Aliment Pharmacol Ther. 2024. PMID: 39523981. doi:10.1111/apt.18383

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。